Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
Rezo Therapeutics’ $78 Million Series A Financing
Zenas BioPharma’s $118 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised lead investor Enavate Sciences and new investor Longitude Capital in the financing. Global pharmaceutical company Zenas BioPharma announced a $118...
Inversago Pharma’s $70 Million Series C Financing
White & Case and Osler, Hoskin & Harcourt LLP advised Inversago Pharma Inc. on the deal, while Wilson Sonsini advised NEA. Inversago Pharma Inc., a clinical-stage...
Aadi Bioscience’s $72.5 Million Private Placement Equity Financing
Wilson Sonsini represented Aadi Bioscience, Inc. on the deal. Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in...
Arcellx’s $112 Million Public Offering
Wilson Sonsini advised Arcellx on the deal. Arcellx, a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other...
Simcha Therapeutics’ $40 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
BIOMILQ, Inc.’s $21 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the deal. North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in...
858 Therapeutics’ $60 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised New Enterprise Associates (NEA) and Versant Ventures on the deal. 858 Therapeutics announced the completion of a $60 million Series...
Attralus’ $116 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Logos Capital on the deal while Sidley represented Attralus, Inc. Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines...
ADARx’s $75 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One Capital Management on the deal. ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion...
ARS Pharmaceuticals’ $55 Million Series D Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better...
Zentera Therapeutics’ $75 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Tybourne Capital Management on the deal. Zentera Therapeutics, a clinical-stage biopharmaceutical company, completed a $75 million Series B financing. Founding investors...